Document Detail

Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.
MedLine Citation:
PMID:  20335789     Owner:  NLM     Status:  MEDLINE    
A retrospective cohort study was conducted to determine if there is an association between short-acting intramuscular (SAIM) antipsychotics used for acute agitation and length of stay (LOS). Patients with a diagnosis of schizophrenia or schizoaffective disorder who were dispensed at least one dose of a SAIM antipsychotic were divided into groups based on the initial SAIM antipsychotic received once admitted to a psychiatric unit. Electronic records were used to gather demographic information, LOS, and number of injections received during an admission. Cost was calculated from the number of injections received. One-hundred and thirty-six patients were enrolled. When comparing the haloperidol group to the second generation antipsychotic group, there was no statistically significant difference, in LOS 16.98 ± 9.56 days versus 17.59 ± 11.52 days (P = 0.75), respectively. There was a statistically significant difference in both cost and number of injections between groups, favoring the haloperidol group. Ziprasidone was associated with a shorter LOS compared with olanzapine, 13.57 and 19.10 days, respectively (P = 0.026). Patient characteristics should be evaluated when determining an agent for acute agitation. However, because literature indicates second generation SAIM antipsychotics are only noninferior to haloperidol; other factors should also be evaluated; including impact on LOS and impact on hospital resources. This study indicates use of a second generation SAIM antipsychotic for acute agitation is more costly, requires more injections, and was not associated with a shorter length of stay when compared with SAIM haloperidol.
Jonathan G Leung; Amanda M Benedetti; Lawrence A Frazee; Nancy Myers
Related Documents :
2704509 - The application of a computer data base system to the generation of hospital discharge ...
15239219 - Ceftriaxone is twice as cost-effective as standard therapy in biliary tract infection.
17559739 - The cost of treating ribavirin-induced anemia in hepatitis c: the impact of using recom...
19298219 - Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis ...
15323579 - Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leuk...
19916729 - Retrospective study of total healthcare costs associated with chronic nonvalvular atria...
15875929 - Predictors of relapse among pulmonary tuberculosis patients treated in a dots programme...
15531349 - Long-term outcome after discontinuation of benzodiazepines for insomnia: a survival ana...
22208179 - Delayed high-quality cpr does not improve outcomes.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  American journal of therapeutics     Volume:  18     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-11     Completed Date:  2012-01-24     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  300-4     Citation Subset:  IM    
Virginia Commonwealth University Health System, Richmond, VA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / administration & dosage,  economics*,  therapeutic use
Benzodiazepines / economics,  therapeutic use
Cohort Studies
Drug Costs*
Haloperidol / economics,  therapeutic use
Injections, Intramuscular
Length of Stay / economics,  statistics & numerical data*
Middle Aged
Piperazines / economics,  therapeutic use
Psychomotor Agitation / drug therapy*
Quinolones / economics,  therapeutic use
Retrospective Studies
Schizophrenia / drug therapy*
Thiazoles / economics,  therapeutic use
Reg. No./Substance:
0/Antipsychotic Agents; 0/Piperazines; 0/Quinolones; 0/Thiazoles; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 52-86-8/Haloperidol; 6UKA5VEJ6X/ziprasidone; 82VFR53I78/aripiprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chemotherapy versus surgery in primary B-cell lymphoma masquerading as klatskin tumor-a diagnostic a...
Next Document:  Drug development in oncology: a regulatory perspective.